The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder

Psychiatric Genetics

Volumn 25, Issue 5, 2015, Pages 201-207

  Moreira, Fernanda P ^a   Fabião, Júlia D ^a   Bittencourt, Guilherme ^a   Wiener, Carolina D ^a   Jansen, Karen ^a   Oses, Jean P ^a   De Ávila Quevedo, Luciana ^a   Souza, Luciano D M ^a   Crispim, Daisy ^c   Portela, Luiz V ^d   Pinheiro, Ricardo T ^a   Lara, Diogo R ^b   Kaster, Manuella P ^a   Da Silva, Ricardo A ^a   Ghisleni, Gabriele ^a  

^a CATHOLIC UNIVERSITY OF PELOTAS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Endocrinology Service   (United States)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

anxiety disorders; brain derived neurotrophic factor; brain derived neurotrophic factor serum levels; generalized anxiety disorder; Val66Met polymorphism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; METHIONINE; VALINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENERALIZED ANXIETY DISORDER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; NERVE CELL PLASTICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ANXIETY DISORDER; BLOOD; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; YOUNG ADULT;

ADULT; ALLELES; ANXIETY DISORDERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; METHIONINE; POLYMORPHISM, SINGLE NUCLEOTIDE; VALINE; YOUNG ADULT;

EID: 84940996700     PISSN: 09558829     EISSN: 14735873     Source Type: Journal    
DOI: 10.1097/YPG.0000000000000097     Document Type: Article

References (54)

1. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association.
2. Andero R, Ressler KJ (2012). Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav 11: 503-512.
3. Arias B, Aguilera M, Moya J, S?iz P, Villa H, Ib?ñez M, et al. (2012). The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxietyrelated traits. Acta Psychiat Scand 125: 194-202.
4. Ball S, Marangell LB, Lipsius S, Russell JM (2013). Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 43: 217-221.
5. Bhang S, Ahn JH, Choi SW (2011). Brain-derived neurotrophic factor and serotonin transporter gene-linked promoter region genes alter serum levels of brain-derived neurotrophic factor in humans. J Affect Disord 128: 299-304.
6. Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, Alesci S, et al. (2011). Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J Clin Psychiatry 72: 1124-1128.
7. Buchmann AF, Hellweg R, Rietschel M, Treutlein J, Witt SH, Zimmermann US, et al. (2013). BDNF Val66Met and 5-HTTLPR genotype moderate the impact of early psychosocial adversity on plasma brain-derived neurotrophic factor and depressive symptoms: a prospective study. Eur Neuropsychopharmacol 23: 902-909.
8. Bus BA, Arias-Vasquez A, Franke B, Prickaerts J, de Graaf J, Voshaar RC (2012). Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males. Neuropsychobiology 65: 183-187.
9. Casarotto PC, De Bortoli VC, Zangrossi H JR (2012). Intrahippocampal injection of brain-derived neurotrophic factor increases anxiety-related, but not panicrelated defensive responses: involvement of serotonin. Behav Pharmacol 23: 80-88.
10. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004). Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24: 4401-4411.
11. Chi MH, Chang HH, Lee SY, Lee IH, Gean PW, Yang YK, et al. (2010). Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. J Affect Disord 126: 430-435.
12. Dalle Molle R, Portella AK, Goldani MZ, Kapczinski FP, Leistner-Segal S, Salum GA, et al. (2012). Associations between parenting behavior and anxiety in a rodent model and a clinical sample: relationship to peripheral BDNF levels. Transl Psychiatry 2: e195.
13. Del'Osso L, Carmassi C, Del Debbio A, Del Debbio A, Catena Dell'Osso M, Bianchi C, da Pozzo E, et al. (2009). Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 33: 899-902.
14. Dos Santos IM, Ciulla L, Braga D, Ceresér KM, Gama CS, Kapczinski F, Ferr?o YA (2011). Symptom dimensional approach and BDNF in unmedicated obsessive-compulsive patients: an exploratory study. CNS Spectr 16: 179-189.
15. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59: 1116-1127.
16. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112: 257-269.
17. Enoch MA, White KV, Waheed J, Goldman D (2008). Neurophysiological and genetic distinctions between pure and comorbid anxiety disorders. Depress Anxiety 25: 383-392.
18. Frustaci A, Pozzi G, Gianfagna F, Manzoli L, Boccia S (2008). Meta-analysis of the brain-derived neurotrophic factor gene (BDNF) Val66Met polymorphism in anxiety disorders and anxiety-related personality traits. Neuropsychobiology 58: 163-170.
19. Fullana MA, Alonso P, Gratac?s M, Jaurrieta N, Jiménez-Murcia S, Segal?s C, et al. (2012). Variation in the BDNF Val66Met polymorphism and response to cognitive-behavior therapy in obsessive-compulsive disorder. Eur Psychiatry 27: 386-390.
20. Gatt JM, Nemeroff CB, Dobson-Stone C, Paul RH, Bryant RA, Schofield PR, et al. (2009). Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry 14: 681-695.
21. Grabe HJ, Schwahn C, Mahler J, Appel K, Schulz A, Spitzer C, et al. (2012). Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Prog Neuropsychopharmacol Biol Psychiatry 36: 264-270.
22. Gratac?s M, Soria V, Urretavizcaya M, Gonz?lez JR, Crespo JM, Bayés M, et al. (2008). A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J 8: 101-112.
23. Hartmann M, Heumann R, Lessmann V (2001). Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. EMBO J 20: 5887-5897.
24. Hashimoto K (2007). BDNF variant linked to anxiety-related behaviors. Bioessays 29: 116-119.
25. Hauck S, Kapczinski F, Roesler R, de Moura Silveira E Jr, Magalhes PV, Kruel LR, et al. (2010). Serum brain-derived neurotrophic factor in patients with trauma psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 34: 459-462.
26. Hosang GM, Shiles C, Tansey KE, McGuffin P, Uher R (2014). Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med 12: 7-7.
27. Hünnerkopf R, Strobel A, Gutknecht L, Brocke B, Lesch KP (2007). Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Neuropsychopharmacology 32: 2552-2560.
28. Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF, et al. (2005). BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30: 1353-1361.
29. Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, et al. (2005). BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology 65: 1823-1825.
30. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62: 593-602.
31. Lahiri DK, Nurnberger JI Jr (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19: 5444.
32. Lam P, Cheng CY, Hong CJ, Tsai SJ (2004). Association study of a brain-derived neurotrophic factor (Val66Met) genetic polymorphism and panic disorder. Neuropsychobiology 49: 178-181.
33. Lang UE, Hellweg R, Sander T, Gallinat J (2009). The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 14: 120-122.
34. Lopez JP, Mamdani F, Labonte B, Beaulieu MM, Yang JP, Berlim MT, et al. (2013). Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry 18: 398-399.
35. Miyajima F, Ollier W, Mayes A, Jackson A, Thacker N, Rabbitt P, et al. (2008). Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly. Genes Brain Behav 7: 411-417.
36. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Prickaerts J, Oude Voshaar RC, Elzinga BM (2012). Gender specific associations of serum levels of brain-derived neurotrophic factor in anxiety. World J Biol Psychiatry 13: 535-543.
37. Nagata T, Shinagawa S, Nukariya K, Yamada H, Nakayama K (2012). Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease. Dement Geriatr Cogn Disord 33: 266-272.
38. Notaras M, Hill R, van den Buuse M (2015). The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy. Mol Psychiatry. 2015 Mar 31. doi: 10.1038/mp.2015.27. [Epub ahead of print].
39. Quesseveur G, David DJ, Gaillard MC, Pla P, Wu MV, Nguyen HT, et al. (2013). BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry 3: e253.
40. Rasmusson AM, Shi L, Duman R (2002). Downregulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with footshock. Neuropsychopharmacology 27: 133-142.
41. Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB, et al. (2005). Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58: 307-314.
42. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20): 22-33.
43. Skibinska M, Hauser J, Czerski PM, Leszczynska-Rodziewicz A, Kosmowska M, Kapelski P, et al. (2004). Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder. World J Biol Psychiatry 5: 215-220.
44. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, et al. (2010). A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327: 863-866.
45. Suliman S, Hemmings SM, Seedat S (2013). Brain-derived neurotrophic factor (BDNF) protein levels in anxiety disorders: systematic review and metaregression analysis. Front Integr Neurosci 7: 55.
46. Surtees PG, Wainwright NW, Willis-Owen SA, Sandhu MS, Luben R, Day NE, Flint J (2007). No association between the BDNF Val66Met polymorphism and mood status in a non-clinical community sample of 7389 older adults. J Psychiatr Res 41: 404-409.
47. Szeszko PR, Lipsky R, Mentschel C, Robinson D, Gunduz-Bruce H, Sevy S, et al. (2005). Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 10: 631-636.
48. Takei S, Morinobu S, Yamamoto S, Fuchikami M, Matsumoto T, Yamawaki S (2011). Enhanced hippocampal BDNF/TrkB signaling in response to fear conditioning in an animal model of posttraumatic stress disorder. J Psychiatr Res 45: 460-468.
49. Tempesta D, Mazza M, Serroni N, Moschetta FS, Di Giannantonio M, Ferrara M, De Berardis D (2013). Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry 45: 236-241.
50. Tocchetto A, Salum GA, Blaya C, Teche S, Isolan L, Bortoluzzi A, et al. (2011). Evidence of association between Val66Met polymorphism at BDNF gene and anxiety disorders in a community sample of children and adolescents. Neurosci Lett 502: 197-200.
51. Tükel R, Gürvit H, Ozata B, Oztürk N, Ertekin BA, Ertekin E, et al. (2012). Brainderived neurotrophic factor gene Val66Met polymorphism and cognitive function in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 159B: 850-858.
52. Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB (2014). Adequacy of treatment received by primary care patients with anxiety disorders. Depress Anxiety 31: 443-450.
53. Yoshii A, Constantine-Paton M (2010). Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol 70: 304-322.
54. Zai G, Arnold P, Strauss J, King N, Burroughs E, Richter MA, Kennedy JL (2005). No association between brain-derived neurotrophic factor gene and obsessive-compulsive disorder. Psychiatr Genet 15: 235.